Primary nephrotic syndrome in adults, including minimal-change nephrotic syndrome, has an incidence of roughly 0.2 to 0.8 per ...

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

Patients with nephrotic syndrome were far more likely than healthy controls to suffer end-stage kidney disease, particularly if they had focal segmental glomerulosclerosis or membranous nephropathy.

One monoclonal antibody, rituximab, can work wonders for the treatment of children with frequently relapsing nephrotic ...

Topline data were announced from a phase 3 study evaluating obinutuzumab in patients between 2 and 25 years of age with idiopathic nephrotic syndrome.

Please provide your email address to receive an email when new articles are posted on . Compared with a cohort free of kidney disease, patients with primary nephrotic syndrome were nearly 20-times ...

– Gazyva versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete remission at week 52 – – If approved, Gazyva could help children and young adults ...

Researchers from The University of Osaka have found that rituximab, a monoclonal antibody approved for the treatment of ...

If approved, Gazyva/Gazyvaro could help children and young adults sustain remission, potentially with a reduced need for steroids to manage their disease 1 INShore is the first global phase III study ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

– If approved, Gazyva could help children and young adults sustain remission, potentially with a reduced need for steroids to manage their disease – – INShore is the first global Phase III study of a ...